Pharvaris (PHVS) is scheduled to present at the US Hereditary Angioedema Association's 2025 National Summit on July 11, 2025.
The company's lead drug candidate is Deucrictibant, a novel, potent, oral small-molecule bradykinin B2 receptor antagonist, being developed in two distinct formulations to address unmet needs in both the on-demand (via immediate-release capsule) and prophylactic (via extended-release tablet) hereditary angioedema treatment paradigms.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.